Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 June 2024 | Story Precious Shamase | Photo Supplied
Prof Richard Ocaya
Prof Richard Ocaya, Associate Professor from the Physics Department.

Prof Richard Ocaya from the Faculty of Natural and Agricultural Sciences at the University of the Free State (UFS) Qwaqwa  Campus has achieved a significant milestone with a newly patented invention. This patent, developed in collaboration with researchers from Turkey and Saudi Arabia, is the result of work that began in 2017, focusing on a special material known as graphitic carbon nitride.

This breakthrough in temperature measurement technology aligns perfectly with the university's Vision 130 commitment to innovation and addressing global challenges. The new device offers a unique solution to a longstanding issue in the field, providing accurate temperature measurements across an extremely wide range. Existing solutions often require multiple devices, leading to increased costs and reduced accuracy, but this invention simplifies the process.

The device, based on a combination of graphitic carbon nitride and silicon, can measure temperatures from -250°C to 250°C with exceptional consistency and linearity. This range and accuracy set it apart from current technologies, making it suitable for various applications, from standard temperature measurement to specialized settings involving extreme temperatures. It could be especially valuable in deep-space exploration, where equipment faces drastic temperature fluctuations.

The patent underscores the university's commitment to fostering collaborative research, a key aspect of Vision 130. Prof Ocaya attributes the success of the invention to the robust nature of the team, established in 2015. The team is now seeking to commercialize the technology by licensing it to a suitable partner, with organizations like NASA expected to show significant interest.

Prof Ocaya advises other academics considering patenting their inventions to ensure the patent solves a real problem uniquely and is based on sound principles. This makes the invention reproducible and protects it from being copied, assigning exclusive rights to the patent holder. Patenting allows for either manufacturing the devices or licensing them to third parties for royalties and profit. He notes that the main consideration is that the innovation must be practical and solve a specific problem in a novel and commercially viable way. He also acknowledges the challenge many academics face, as the "publish or perish" mentality often leads to choosing scientific articles over patents.

Despite securing the patent, Prof Ocaya and his team continue their research efforts, exploring new possibilities while balancing practical research with academic pursuits. He believes the invention will significantly impact the field of temperature measurement, being integrated into many new designs requiring such measurements.

The university proudly supports this innovative research and anticipates its real-world impact, furthering Vision 130's commitment to increasing UFS's research capacity and capability.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept